A prospective evaluation of the biochemical, metabolic, hormonal and structural bone changes associated with bortezomib response in multiple myeloma patients
We prospectively evaluated the bone changes associated with proteasome inhibition using single agent bortezomib in relapsed or refractory myeloma patients. Ten patients received bortezomib 1.3 mg/m(2) per days 1, 4, 8 and 11 for three 21-day cycles, and 6 patients received 1 mg/m(2) per day with the same schedule. Bone architecture and metabolism changes were assessed by bone markers, micro-CT, bone histomorphometry, tetracycline labeling and serum parathormone levels. Bone parameter variations were compared by response to treatment. Microarchitectural changes were observed in all evaluable responsive patients. Bone alkaline phosphatase changes were associated with disease response (≥PR vs. others P=0.03 cycle 1, day 11) serum parathormone levels were also significantly increased (P=0.04 on days 11, 21, 33) in responding individuals. This study demonstrates that the myeloma control produced by proteasome inhibition is associated with bone changes and to a discrete pattern of hormonal variation.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2011 |
|---|---|
| Erschienen: |
2011 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:96 |
|---|---|
| Enthalten in: |
Haematologica - 96(2011), 2 vom: 01. Feb., Seite 333-6 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Zangari, Maurizio [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 27.09.2011 Date Revised 20.10.2021 published: Print-Electronic ClinicalTrials.gov: NCT00569868 Citation Status MEDLINE |
|---|
| doi: |
10.3324/haematol.2010.031302 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM202430715 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM202430715 | ||
| 003 | DE-627 | ||
| 005 | 20231223224310.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231223s2011 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3324/haematol.2010.031302 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0675.xml |
| 035 | |a (DE-627)NLM202430715 | ||
| 035 | |a (NLM)20952514 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Zangari, Maurizio |e verfasserin |4 aut | |
| 245 | 1 | 2 | |a A prospective evaluation of the biochemical, metabolic, hormonal and structural bone changes associated with bortezomib response in multiple myeloma patients |
| 264 | 1 | |c 2011 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 27.09.2011 | ||
| 500 | |a Date Revised 20.10.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a ClinicalTrials.gov: NCT00569868 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a We prospectively evaluated the bone changes associated with proteasome inhibition using single agent bortezomib in relapsed or refractory myeloma patients. Ten patients received bortezomib 1.3 mg/m(2) per days 1, 4, 8 and 11 for three 21-day cycles, and 6 patients received 1 mg/m(2) per day with the same schedule. Bone architecture and metabolism changes were assessed by bone markers, micro-CT, bone histomorphometry, tetracycline labeling and serum parathormone levels. Bone parameter variations were compared by response to treatment. Microarchitectural changes were observed in all evaluable responsive patients. Bone alkaline phosphatase changes were associated with disease response (≥PR vs. others P=0.03 cycle 1, day 11) serum parathormone levels were also significantly increased (P=0.04 on days 11, 21, 33) in responding individuals. This study demonstrates that the myeloma control produced by proteasome inhibition is associated with bone changes and to a discrete pattern of hormonal variation | ||
| 650 | 4 | |a Evaluation Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Biomarkers |2 NLM | |
| 650 | 7 | |a Boronic Acids |2 NLM | |
| 650 | 7 | |a Parathyroid Hormone |2 NLM | |
| 650 | 7 | |a Protease Inhibitors |2 NLM | |
| 650 | 7 | |a Pyrazines |2 NLM | |
| 650 | 7 | |a Bortezomib |2 NLM | |
| 650 | 7 | |a 69G8BD63PP |2 NLM | |
| 650 | 7 | |a Alkaline Phosphatase |2 NLM | |
| 650 | 7 | |a EC 3.1.3.1 |2 NLM | |
| 700 | 1 | |a Yaccoby, Shmuel |e verfasserin |4 aut | |
| 700 | 1 | |a Pappas, Lisa |e verfasserin |4 aut | |
| 700 | 1 | |a Cavallo, Federica |e verfasserin |4 aut | |
| 700 | 1 | |a Kumar, Naveen Sanath |e verfasserin |4 aut | |
| 700 | 1 | |a Ranganathan, Subramanian |e verfasserin |4 aut | |
| 700 | 1 | |a Suva, Larry J |e verfasserin |4 aut | |
| 700 | 1 | |a Gruenwald, J Michael |e verfasserin |4 aut | |
| 700 | 1 | |a Kern, Steven |e verfasserin |4 aut | |
| 700 | 1 | |a Zhan, Fenghuang |e verfasserin |4 aut | |
| 700 | 1 | |a Esseltine, Dixie |e verfasserin |4 aut | |
| 700 | 1 | |a Tricot, Guido |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Haematologica |d 1947 |g 96(2011), 2 vom: 01. Feb., Seite 333-6 |w (DE-627)NLM000081892 |x 1592-8721 |7 nnns |
| 773 | 1 | 8 | |g volume:96 |g year:2011 |g number:2 |g day:01 |g month:02 |g pages:333-6 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3324/haematol.2010.031302 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 96 |j 2011 |e 2 |b 01 |c 02 |h 333-6 | ||